Because patients under chemotherapy as frontline treatment are at risk of developing neutropenia (Blayney and Schwartzberg, 2022), G-CSF is often administered to foster neutrophil production and their egress from the bone marrow (Mehta et al, 2015), (Lambertini et al, 2015). Here, CSF3 is linked to neutropenia.